Summary We will be interviewing an academic rheumatologist familiar with SEL-212 (Selecta) and Horizon’s Krystexxa and has experience in managing chronic refractory gout. This call will address the probability of success, especially in the high-dose cohort from the additional Phase 2 data for SEL-212 in chronic refractory gout. This article will also provide a pre-call primer on Selecta Biosciences, their …

James M. Wilson, M.D., Ph.D., has joined the Gene Therapy Consortium of the Rett Syndrome Research Trust (RSRT), the Trust said today. The announcement came 10 days after the separate disclosure that he resigned from the Scientific Advisory Board of Solid Biosciences, which is set to begin an initial public offering (IPO) today. RSRT said it will fund the research …

Summary ARMO BioSciences intends to raise $100 million in a U.S. IPO. The firm is developing a promising pipeline of immuno-based treatments for some of the deadliest forms of cancer. Given the potential of its lead candidate, its late stage of development and existing investor support of the IPO, ARMO may have a winning drug treatment. Quick Take ARMO BioSciences (ARMO) …

Summary Shares have risen by 55% since initially presenting the idea to readers. I recap the bullish thesis and remind readers of the untapped potential for Ingrezza. The company´s pediatric Tourette syndrome program is progressing nicely despite a clinical ¨hiccup¨. Management appears to be executing solidly on their game plan considering the so far successful launch of Ingrezza and progression …

Cancer Immunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO Armo BioSciences, a late-stage developer of cancer immunotherapies, will seek to raise up to $86.25 million in gross proceeds through an initial public offering, according to an S-1 registration statement filed with the U.S. Securities and Exchange Commission on the last business day of 2017. Armo has yet to spell out …

Neurocrine Biosciences: Continued Upside In 2018 Summary Shares have risen by 55% since initially presenting the idea to readers. I recap the bullish thesis and remind readers of the untapped potential for Ingrezza. The company´s pediatric Tourette syndrome program is progressing nicely despite a clinical ¨hiccup¨. Management appears to be executing solidly on their game plan considering the so far …

Lumen raises $13M for spirulina extract eattle, WA-based Lumen Bioscience, a synthetic biotechnology company developing a novel bio-based product development platform, has raised $13 million of new capital, including a Series A investment round totaling $11.2M and a $1.8M grant from the US Department of Energy. The financing was led by Avista Development, BioEconomy Capital, company founders and other Seattle-area …

Locus Biosciences, developer of a next-generation CRISPR/Cas platform for precision antimicrobials, has closed $19 million in Series A funding designed to fund the company through filing its first Investigational New Drug (IND), as well as a subsequent first-in-human trial. A spinout of North Carolina State University (NCSU) founded in 2015, Locus Biosciences designs and creates novel CRISPR RNAs or “smart …

Infectious diseases: CTRL + ALT + Delete Gene editing is revolutionizing the bioscience research landscape and holds great promise for “deleting” diseases from human bodies. Sandia National Laboratories is working to make this technology safer and to ensure that one day it can be delivered into humans without triggering adverse immune system reactions or causing other undesirable side effects. Sandia …

Mutation not genetic modification could revive EU bioscience A “LANDMARK opinion” from the European Court of Justice on the definition of genetically modified organisms could pave the way for a revival of crop biotechnology in Europe. According to Rothamsted Research’s senior plant geneticist, Professor Nigel Halford, the ambiguities of legislation in Europe have long caused problems for biotechnology, but this …